Clinical Trial to Assess Onset of Action of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray Delivered in a Single Spray (MP-AzeFlu) in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in Comparison to Placebo and Free Combination of Fluticasone Propionate Nasal Spray and Oral Loratadine
Phase of Trial: Phase IV
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Azelastine/fluticasone-propionate (Primary) ; Fluticasone propionate; Loratadine
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Meda Pharma GmbH & Co KG
- 05 Mar 2018 Primary endpoint [Total Nasal Symptom Score (TNSS); change from baseline over the last 4 hours of exposure in an Environmental Exposure Chamber (EEC)] has been met, according to the results presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 05 Mar 2018 Results presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 27 Mar 2017 Status changed from recruiting to completed.